Business Description
Fennec Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA31447P1009
Description
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.26 | |||||
| Equity-to-Asset | -0.09 | |||||
| Debt-to-Equity | -6.21 | |||||
| Debt-to-EBITDA | 8.72 | |||||
| Interest Coverage | 0.38 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -1.55 | |||||
| Beneish M-Score | 0.05 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 392.2 | |||||
| 3-Year EBITDA Growth Rate | 13.9 | |||||
| 3-Year EPS without NRI Growth Rate | 6.4 | |||||
| 3-Year FCF Growth Rate | -0.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 55.39 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.25 | |||||
| 9-Day RSI | 72.06 | |||||
| 14-Day RSI | 69.55 | |||||
| 6-1 Month Momentum % | -32.44 | |||||
| 12-1 Month Momentum % | -48.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.8 | |||||
| Quick Ratio | 7.65 | |||||
| Cash Ratio | 5.42 | |||||
| Days Inventory | 210.88 | |||||
| Days Sales Outstanding | 72.35 | |||||
| Days Payable | 461.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.3 | |||||
| Shareholder Yield % | -3.71 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93.51 | |||||
| Operating Margin % | 3.09 | |||||
| Net Margin % | -2.4 | |||||
| FCF Margin % | 47.68 | |||||
| ROA % | -2.49 | |||||
| ROIC % | 18.39 | |||||
| ROC (Joel Greenblatt) % | 37.77 | |||||
| ROCE % | 7.06 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 62.48 | |||||
| PS Ratio | 3.66 | |||||
| Price-to-Free-Cash-Flow | 9.11 | |||||
| Price-to-Operating-Cash-Flow | 9.11 | |||||
| EV-to-EBIT | 57.21 | |||||
| EV-to-EBITDA | 44.11 | |||||
| EV-to-Revenue | 3.29 | |||||
| EV-to-Forward-Revenue | 3.06 | |||||
| EV-to-FCF | 6.91 | |||||
| Earnings Yield (Greenblatt) % | 1.75 | |||||
| FCF Yield % | 13.76 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fennec Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 66.81 | ||
| EPS (TTM) (C$) | -0.137 | ||
| Beta | 0.92 | ||
| Volatility % | 68.5 | ||
| 14-Day RSI | 69.55 | ||
| 14-Day ATR (C$) | 0.428591 | ||
| 20-Day SMA (C$) | 6.9665 | ||
| 12-1 Month Momentum % | -48.61 | ||
| 52-Week Range (C$) | 5.65 - 15.43 | ||
| Shares Outstanding (Mil) | 27.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fennec Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fennec Pharmaceuticals Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Fennec Pharmaceuticals Inc Frequently Asked Questions
What is Fennec Pharmaceuticals Inc(TSX:FRX)'s stock price today?
The current price of TSX:FRX is C$8.44. The 52 week high of TSX:FRX is C$15.43 and 52 week low is C$5.65.
When is next earnings date of Fennec Pharmaceuticals Inc(TSX:FRX)?
The next earnings date of Fennec Pharmaceuticals Inc(TSX:FRX) is 2025-03-21 Est..
Does Fennec Pharmaceuticals Inc(TSX:FRX) pay dividends? If so, how much?
Fennec Pharmaceuticals Inc(TSX:FRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers